I was diagnosed with MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) in 2022 via biopsy after persistently elevated liver enzymes. NAS score of 5 (steatosis 2, lobular inflammation 2, ballooning 1) with stage F2 fibrosis. Basically: significant fatty liver disease with active inflammation and early scarring.

Started semaglutide 2.4 mg in early 2024. Here's my liver panel trajectory:

My hepatologist ordered a repeat FibroScan at month 12: CAP score dropped from 348 dB/m (severe steatosis) to 218 dB/m (mild steatosis). Liver stiffness went from 9.8 kPa (F2-F3) to 6.4 kPa (F0-F1).

I also lost 62 lbs (SW: 258 → CW: 196, 24% loss). My hepatologist says the imaging and labs are "consistent with MASH resolution" and is considering whether a repeat biopsy is warranted.

This is an outstanding response and it aligns with the Phase 2 trial data for semaglutide in MASH. In the semaglutide Phase 2b MASH trial, 59% of patients on semaglutide 0.4 mg daily achieved MASH resolution (defined as NAS ≤2 with no hepatocyte ballooning) vs. 17% on placebo.^[1]

Your FibroScan improvements are particularly encouraging:

• CAP 348 → 218 dB/m: This represents a shift from S3 (severe) to S1 (mild) steatosis. That's a dramatic reduction in hepatic fat content.
• Stiffness 9.8 → 6.4 kPa: Crossing from F2-F3 to F0-F1 territory suggests fibrosis regression, which is the holy grail of MASH treatment. Fibrosis stage is the strongest predictor of liver-related mortality.

The mechanism involves multiple pathways: reduced de novo lipogenesis (from improved hepatic insulin sensitivity), increased fatty acid oxidation, reduced hepatic inflammation, and potentially direct anti-fibrotic effects through hepatic stellate cell modulation.

^[1] Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.

Regarding the repeat biopsy question: there's growing consensus that non-invasive testing (FibroScan + serum markers like FIB-4 and ELF score) can adequately monitor treatment response without subjecting patients to repeat biopsies. The AASLD is evolving its guidance on this.

Your FIB-4 improvement from 2.8 to 1.1 is very reassuring. A FIB-4 <1.3 has a >90% negative predictive value for advanced fibrosis. Combined with the FibroScan improvement, I think a repeat biopsy is reasonable to confirm resolution but probably not strictly necessary from a management standpoint.

The one scenario where I'd push for biopsy: if there's consideration of stopping semaglutide. Having histological confirmation of resolution would provide confidence that the underlying disease is truly addressed, not just biochemically suppressed.

For context, here's the current therapeutic landscape for MASH and where GLP-1 agonists fit:

Tirzepatide's Phase 2 MASH data (SYNERGY-NASH) showed the highest resolution rates of any agent studied, likely due to the dual GIP/GLP-1 mechanism and greater weight loss. Phase 3 trials are ongoing and highly anticipated.

The tirzepatide MASH numbers are incredible. 74% resolution rate? I wonder if patients with more advanced fibrosis (F3-F4) would see similar benefit, or if there's a point of no return where the fibrosis is too established to reverse.